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Juvenile hyaline ﬁbromatosis (JHF) and infantile systemic hyalinosis (ISH) are autosomal recessive conditions
characterized by multiple subcutaneous skin nodules, gingival hypertrophy, joint contractures, and hyaline depo-
sition. We previously mapped the gene for JHF to chromosome 4q21. We now report the identiﬁcation of 15
different mutations in the gene encoding capillary morphogenesis protein 2 (CMG2) in 17 families with JHF or
ISH. CMG2 is a transmembrane protein that is induced during capillary morphogenesis and that binds laminin
and collagen IV via a von Willebrand factor type A (vWA) domain. Of interest, CMG2 also functions as a cellular
receptor for anthrax toxin. Preliminary genotype-phenotype analyses suggest that abrogation of binding by the
vWA domain results in severe disease typical of ISH, whereas in-frame mutations affecting a novel, highly conserved
cytoplasmic domain result in a milder phenotype. These data (1) demonstrate that JHF and ISH are allelic conditions
and (2) implicate perturbation of basement-membrane matrix assembly as the cause of the characteristic perivascular
hyaline deposition seen in these conditions.
Introduction
Juvenile hyaline ﬁbromatosis (JHF [MIM 228600]) is an
autosomal recessive condition that usually presents with
nodular/papular skin lesions and gingival hypertrophy
during the ﬁrst few years of life. The skin lesions typically
occur on the hands, scalp, and ears and around the nose
and require recurrent excision. Progressive joint contrac-
tures and osteopenia are characteristic and may result in
severe limitation of mobility. The diagnosis is conﬁrmed
by demonstration of hyaline deposition in the dermis
(Keser et al. 1999; Mancini et al. 1999; Allen 2001; Rah-
man et al. 2002). The origin and nature of the amorphous
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hyaline material have been unclear, but it appears to be
principally composed of glycoproteins and glycosamino-
glycans (Ishikawa et al. 1979;Mayer-da-Silva et al. 1988).
Infantile systemic hyalinosis (ISH [MIM 236490])
is an autosomal recessive condition that shares many
similarities with JHF. Clinical presentation is usually
at birth or within the ﬁrst few months, with painful,
swollen joint contractures and livid red hyperpigmen-
tation over bony prominences. Pearly papules (predom-
inantly of the face, scalp, and neck) and ﬂeshy nodules
(particularly in the perianal region) then develop. Gin-
gival hypertrophy and thickened skin are also charac-
teristic features. Osteopenia is often present and results
in increased susceptibility to bone fractures. Affected
children are susceptible to infections and/or intractable
diarrhea due to protein-losing enteropathy, and many
die in infancy from resulting multisystem failure. Chil-
dren with ISH are intellectually normal; if they survive
infancy, they become less susceptible to infection, and
their joints may become less painful. However, their
792 Am. J. Hum. Genet. 73:791–800, 2003
mobility remains severely restricted by joint contrac-
tures. Histologically, ISH is also characterized by hy-
aline deposition, but this is more widespread than in
JHF and can affect many tissues, including skin, skele-
tal muscle, cardiac muscle, gastrointestinal tract, lymph
nodes, spleen, thyroid, and adrenal glands (Landing et
al. 1986; Glover et al. 1991, 1992; Sahn et al. 1994;
Stucki et al. 2001).
The underlying pathogenesis of JHF and ISH was pre-
viously unknown. In the past, these conditions have been
postulated to be lysosomal storage disorders (Nezelof et
al. 1978), disorders of abnormal collagen metabolism
(Kayashima et al. 1994; Lubec et al. 1995; Breier et al.
1997), or the result of defective glycosaminoglycan for-
mation (Kitano et al. 1972; Iwata et al. 1980; Remberger
et al. 1985; Breier et al. 1997). However, no consistent
biochemical abnormalities in support of any of these hy-
potheses are reliably present (Stucki et al. 2001).
We previously mapped the gene that causes JHF to
a 7-cM interval on chromosome 4q21 in ﬁve families
(Rahman et al. 2002). We hypothesized that ISH is due
to the same gene as is JHF, and we ascertained and an-
alyzed 11 families with ISH for linkage to chromosome
4q21. These analyses conﬁrmed that JHF and ISH are
allelic and reﬁned the gene interval to 0.85 Mb. Mu-
tation analysis of genes within the minimal interval re-
vealed that deleterious mutations in the gene encoding
capillary morphogenesis protein 2 (CMG2) were the
cause of both conditions.
Subjects and Methods
Subjects
Approval for the study was obtained from the London
Multicentre Research Ethics Committee, and informed
consent was given by all families. In total, 8 families
(A–H) with a clinical diagnosis of JHF and 10 families
(I–R) with a diagnosis of ISH were ascertained. Cases
of JHF were characterized by (1) diagnosis after birth,
typically after 18 mo, (2) joint contractures, (3) nodular
and/or papular skin lesions, (4) gingival hypertrophy,
and (5) histological evidence of hyaline deposition in the
dermis. Cases of ISH were characterized by (1) onset at
birth or in the ﬁrst few months of life, (2) joint con-
tractures, (3) painful diffusely thickened skin, often with
hyperpigmentation over joints, (4) papular and/or nod-
ular skin lesions, (5) gingival hypertrophy, (6) visceral
involvement, and (7) histological evidence of hyaline
deposition. Clinical and histological details from several
of these families have been published previously: families
A, B, and E (Rahman et al. 2002); family C (Keser et al.
1999); families D and F (Mancini et al. 1999); family G
(Balci et al. 2002); family H (Richter et al. 1999); family
L (Stucki et al. 2001); and family Q (Glover et al. 1992).
Control samples were obtained from Human Random
Control DNA panels from the European Collection of
Cell Cultures.
Microsatellite Analysis
DNA was extracted from peripheral blood samples,
using standard procedures. We identiﬁed known chromo-
some 4q21 markers, using the Marshﬁeld Clinic database
(see the Center for Medical Genetics Web site) and the
University of California–Santa Cruz (UCSC)HumanGe-
nome Project Working Draft sequence (see the UCSC
Genome Bioinformatics Web site). We generated new
markers by searching the 7-cM interval encompassing
the JHF gene for dinucleotide, trinucleotide, and tetra-
nucleotide repeat elements, and we designed amplifying
primers, using Primer3 software (table A [available on-
line only]). We identiﬁed 20 novel microsatellitemarkers
that we called “SH-REPs” (systemic hyalinosis repeats).
The order and physical positions of the known and new-
ly generated markers analyzed are shown in ﬁgure 1.
The microsatellite markers were radiolabeled and PCR
ampliﬁed in the families with JHF and ISH, and the
resulting PCR products were electrophoresed through
6% denaturing polyacrylamide gels before exposure to
x-ray ﬁlm.
Mutation Analysis
Amplifying primers ﬂanking the exons and the in-
tron-exon boundaries of the 17 CMG2 exons were
designed using Primer3 software. The primer sequenc-
es and sizes are shown in table 1. Using a Touchdown
68C–50C protocol, we ampliﬁed all products apart
from exon 8, for which the PCR was performed at a
single annealing temperature, of 55C. We used con-
formation-sensitive gel electrophoresis (CSGE) (Gan-
guly et al. 1993) to mutationally screen CMG2 in the
18 families. Genomic DNA from cases showing mo-
bility shifts on CSGE was bidirectionally sequenced
using the BigDyeTerminator Cycle Sequencing Kit and
a 3100 automated sequencer (ABI Perkin Elmer). The
mutations were numbered from the ﬁrst ATG (me-
thionine) of the full-length CMG2 (GenBank acces-
sion number AK091721), with A as nucleotide 1. For
evaluation of the likely pathogenicity of missense and
in-frame alterations, we screened 300 control subjects
from the United Kingdom. Owing to the wide diver-
sity of ethnic groups included in the study, it was not
feasible to obtain sufﬁcient numbers of ethnically
matched control subjects for individual mutations. To
conﬁrm the CMG2 cDNA sequence and the patho-
genicity of splice-site mutations in families A and C,
cDNA was synthesized from RNA extracted from ﬁ-
broblast cell lines, using standard procedures. CMG2
cDNA was sequenced in two fragments, using over-
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Figure 1 Homozygosity mapping and genomic structure of CMG2. a, Homozygosity-mapping data from 18 microsatellite markers on
chromosome 4q21 in consanguineous families with JHF and ISH, showing marker alleles, regions of homozygosity (boxed), and key recom-
bination events in families H and P. The physical distances of the markers according to the November 2002 UCSC Human Genome Project
Working Draft (see the UCSC Genome Bioinformatics Web site) are shown above each marker. b, Partial transcript map (drawn to scale) of
the critical interval, showing currently known genes. c, Genomic structure of full-length CMG2.
lapping primer pairs: CMG2-1F (5′-ACAGCAACTT-
GCGGAGAGAT-3′) and CMG2-1R (5′-TGCAGAGA-
ACACTGCCATTC-3′); and CMG2-2F (5′-GTGGGG-
GAGGAATTTCAGAT-3′) and CMG2-2R (5′-CCTC-
AACAAAGCCCAGAGAG-3′).
Expression Analysis
RT-PCR analysis was performed in duplicate on
normalized multiple-tissue cDNA panels 1 and 2
(Clontech), using primers 5′-ACAGCAACTTGCG-
GAGAGAT-3′ and 5′-AAGCAAAGCAGAAGGCA-
GAG-3′, which amplify exons 2–17 of CMG2. The
recommended Titanium Taq DNA polymerase was
used with a Touchdown protocol 68C–50C for 18
cycles, followed by 14 cycles with annealing at 50C.
Five microliters of product was analyzed by agarose
gel electrophoresis with fX-174 HaeIII digest size
marker.
Bioinformatic Analyses
CMG2 cDNAs were identiﬁed from GenBank and
Ensembl and were aligned against each other, using
ClustalW, and against genomic sequence, using BLAT
(see the Human BLAT Search Web site). The relat-
ed human protein, tumor endothelium marker 8
(TEM8), and orthologous proteins in rat, mouse, and
fugu were identiﬁed using BLAST. The novel cyto-
plasmic domains from pig, cow, and zebraﬁsh were
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Table 1
Primer Pairs Used to Amplify the CMG2 Coding Sequence and Sizes of PCR Products
EXON
PRIMER SEQUENCE
(5′r3′)
SIZE
(bp)Forward Reverse
1 GCTGTGGCTGTTGGTGCT GCTTGCCCTTTGAAAGAAGA 249
2 TTCCGTGTTTTGTTTCTCTGA CAATACGACCTTGAGGCACTT 245
3 AGCCTGGACCATTCAGTGAG ATTCCACTGAGAGGCCTGAA 284
4 TGTTACCTTTGCTCTTTGCTCA TGAGCTTTGCTAGAGGGTTTT 213
5 GCTTGATGGAACATGCTGGT AGCGATGTACAGTGGGGTGT 224
6 CTTTCTCCCTCTCCCCTCTC AACAATCGACCAGTGTCACAA 229
7 TTGTATGTGTCAGCCACTCCTT TAATGACCACCTGCACTGGA 225
8 TGGAGAAGACCTCAAGGTTATTA TTCTTTTTCCAACATGAGTTTCA 249
9 CTTTCATTTCAGCTTGTGTTTTT TGTCAGTTAGTTTTCGTTGGAGA 268
10 TCCACATTTGAACTCTGATTGA TGACCAATGTATATGTCACCATTTT 250
11 TGTTTTCTGGCTGGTTTTGA TTTCTGGATGGAATTGCTTTT 229
12 TTCTGAATTATTTTCTGGTGTTTCC TGGCATTTATTCATATTTCAGACC 276
13 GCAAGCTTCAGTGAGGGACT GCATGGTATCTGCATTTGGA 230
14 TGAGCCAGTTCCGACTAAACA TGGCTTAATAGCCCTAGAAATACAT 229
15 GCCTGTTCCTCTAGGACACTTT GGGGGATGTGGTACAAAAA 300
16 TCTTCGTTTTATGTCTTCATTTATTCA TCCCTGCCTCCATTATACTGAC 227
17 GGAAAACTAGATGTTCTCATGCTTT CATTTCCCGACTGAGAGGAA 247
identiﬁed with tblastn, using the CMG2 protein se-
quence against the National Center for Biotechnol-
ogy Information Expressed Sequence Tags Database,
translated in all six frames. Those sequences showing
homology in one reading frame were aligned using
MultAlin and ClustalW. The Pfam, Prosite, and Con-
served Domain databases were searched for sequenc-
es similar to the CMG2/TEM8 cytoplasmic domain.
Results
Homozygosity Mapping in JHF and ISH Cases
to Reﬁne the Gene Interval
We previously mapped the gene for JHF to a 7-cM
interval between D4S2393 and D4S395 (Rahman et al.
2002). To reﬁne this interval, we developed new mi-
crosatellite markers. Analyses of these markers in the
original families with JHF reduced the gene interval to
a 5-Mb region between SH-REP6 and D4S1553 (data
not shown). We analyzed the 18 known and newly
generated markers within this interval in 12 families
with JHF and ISH that were either known or suspected
to be consanguineous. All analyzed families were ho-
mozygous at multiple markers within the region, con-
sistent with linkage of both JHF and ISH to chromo-
some 4q21. The regions of homozygosity in families H
and P reﬁned the interval encompassing the gene to
0.85 Mb between SH-REP19 and SH-REP14 (ﬁg. 1a).
The minimal region contained four known genes—
GDEP, CMG2, PRDM8, and FGF5 (ﬁg. 1b). We
screened FGF5 but did not identify any likely patho-
genic mutations (data not shown).
Identiﬁcation of a Novel Cytoplasmic Domain
in the Full-Length CMG2
CMG2 is a transmembrane protein with a von Wil-
lebrand factor type A (vWA) domain in the extracel-
lular region. CMG2 was reported elsewhere as a 386-
amino-acid protein expressed only in placenta (Bell et
al. 2001). However, alignment of CMG2 cDNAs and
genomic sequence suggested that a 1.46-kb ORF that
includes four extra exons (8–11) between the vWA do-
main and the transmembrane domain represents the
full-length gene (ﬁg. 1c). This transcript is predicted to
encode a 488-amino-acid protein, which we conﬁrmed
by RT-PCR and cDNA sequencing (ﬁg. 2a). By RT-PCR
of human cDNA multiple-tissue panels, expression of
the transcript was demonstrated in all tissues analyzed
except brain (ﬁg. 2b).
The only known paralog of CMG2 is TEM8, which
shows 56% overall amino acid identity (Scobie et al.
2003). Sequence comparison of CMG2 and TEM8 re-
vealed that the highest level of conservation (80%) oc-
curred at residues 338–421 in the intracellular region
of the protein. Within this cytoplasmic domain, we iden-
tiﬁed a novel 50-amino-acid motif (residues 367–417)
that was almost identical in both human proteins and
orthologs in cow, pig, chicken, mouse, rat, fugu, and
zebraﬁsh (ﬁg. 3). The conserved cytoplasmic domain
did not show signiﬁcant similarity to any known pro-
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Figure 2 Expression of CMG2. a, Sequence of full-length CMG2. b, RT-PCR of human cDNA multiple-tissue panel (Clontech), showing
expression of ∼1.4 kb transcript in all tissues, except brain.
tein motifs in the Pfam, Prosite, or Conserved Domain
databases.
Identiﬁcation of CMG2 Mutations in JHF and ISH
Cases
Genomic DNA from 18 families was screened for
CMG2 mutations by CSGE and direct sequencing. We
identiﬁed 15 different mutations in 17 families (table
2 and ﬁg. 4a). These mutations were predicted to ab-
rogate CMG2 function and consisted of four small in-
sertions or deletions, four mutations that alter consen-
sus splice-junction sequences, one nonsense mutation,
one in-frame insertion of a glutamine residue, and four
nonconservative missense mutations. Using RT-PCR,
we conﬁrmed the pathogenicity of two splice-site mu-
tations: IVS131GrA, which leads to an insertion of
4 bases after exon 13 and a translational frameshift
(ﬁg. 4b); and 1707GrA, a synonymous substitution
that alters a consensus splice-junction base, resulting
in an in-frame deletion of exon 14. The missense mu-
tations were not present in 300 U.K. control subjects
and occurred at residues conserved in both the mouse
ortholog and the human paralog, TEM8 (data not
shown). Moreover, these mutations were present in
families in which homozygosity was present through-
out the linked interval or in which a truncating mu-
tation on the other allele was identiﬁed, indicating that
CMG2 is the causative gene in these families (table 2).
We did not ﬁnd a mutation in family O, but, because
the case subject is homozygous at all of the chromo-
some 4q21 markers analyzed, it is presumed that ab-
rogation of CMG2 function has caused ISH in this
family (ﬁg. 1a). Only one heterozygous mutation was
identiﬁed in families E, J, and M. We assume that a
second CMG2 mutation is present in these families but
was not detected, either because of lack of sensitivity
of the screening technique or because the deleterious
alterations are not detectable by our methods—for ex-
ample, genomic rearrangements or regulatory muta-
tions. It is possible that these cases are compound het-
erozygotes for mutations in two separate genes, but
there is currently no evidence to support genetic het-
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Figure 3 Sequence alignment of 50 amino acids in cytoplasmic domain of CMG2 and TEM8 in various species, showing high conservation.
Black background indicates identical residues, and gray background indicates conservative substitutions. In pig, sheep, chicken, and zebraﬁsh,
the gene that the conserved region is from is currently unknown, because the full-length gene sequence is not available. The position of the
missense mutation in family D is indicated by an arrow.
erogeneity in JHF or ISH, with all of the families thus
far analyzed showing linkage and/or mutation evidence
in support of CMG2 as the causative gene. Identical
founder mutations in families A and B and families C
and F were identiﬁed, consistent with the chromosome
4q21 haplotype data (ﬁg. 1a). Conversely, although a
cytosine insertion in a poly-C tract in exon 13 was
identiﬁed in three separate families, we believe these to
have arisen independently, because the families carry
different chromosome 4q21 haplotypes and CMG2
polymorphisms. Moreover, two further families had
different mutations involving the poly-C tract, which
appears to be a mutational hotspot, presumably owing
to the repetitive sequence (table 2). The mutations seg-
regated with the disease in all families in which this
could be evaluated, and all tested parents of case sub-
jects were carriers, as expected in an autosomal reces-
sive condition. We identiﬁed nine CMG2 sequence var-
iants that (a) did not segregate with the disease, (b)
were present in individuals with two pathogenic mu-
tations, and/or (c) led to intronic changes, and these
were assumed to be innocuous polymorphisms (table 3).
Genotype-Phenotype Analyses
We compared the phenotypes of 14 cases in which
CMG2 mutations on both alleles were identiﬁed (table
2). All cases exhibited hyaline deposition, gingival hy-
pertrophy, and skin nodules/papules. Missense and trun-
cating mutations in the extracellular vWA domain were
associated with a severe phenotype, typically presenting
at birth, characterized by death in infancy from sepsis,
intractable diarrhea, and/or multiorgan failure. Case sub-
jects with at least one insertion/deletionmutationresulting
in a translational frameshift all had the infantile form of
the disease. Conversely, in-frame and missense mutations
in the cytoplasmic domain were associated with a milder
JHF phenotype, presenting in infancy, characterized by
survival to adulthood without recurrent infections, gas-
trointestinal disease, or failure to thrive (ﬁg. 1a and table
2). In particular, the tendoarticular manifestations, which
are the predominant cause of morbidity for those who
survive infancy, were extremely variable. This was ex-
empliﬁed by missense mutations in the vWA domain that
resulted in severely limiting painful contractures (families
L and R), whereas a missense mutation in the cytoplasmic
domain resulted in no skeletal limitation (family D).
Discussion
CMG2 was originally identiﬁed as a gene upregulated
in endothelial cells induced to undergo capillary for-
mation in three-dimensional collagen matrices (Bell et
al. 2001). CMG2 is a type 1 transmembrane protein,
and its extracellular region contains a vWA domain
that shows strong binding to laminin and collagen IV,
both of which are markedly induced in endothelial cell
morphogenesis in a time frame coincident with CMG2
induction (Bell et al. 2001). These data implicate CMG2
in basement-membrane matrix assembly and endothelial
cell morphogenesis and suggest that the hyaline material
deposited between the endothelial cells and pericytes in
ISH and JHF may result from leakage of plasma compo-
nents through the basement membrane to the perivas-
cular space.
Preliminary genotype-phenotype analyses suggest that
the wide phenotypic variability associated with CMG2
abrogationmay be related, at least in part, to the underly-
ing mutational spectrum. The milder JHF cases were as-
sociated with in-frame and missense mutations within
the novel cytoplasmic domain. In contrast, cases inwhich
vWA-domain binding is predicted to be impaired typi-
cally exhibited a more severe form of the disease. These
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Figure 4 Genomic structure, protein domains, and mutation analysis of CMG2. a, Genomic structure and mutations in CMG2 with the
exon sizes drawn to scale and the position of functional and conserved domains indicated (TM p transmembrane). The 5′ and 3′ UTRs are
indicated by open boxes and are not drawn to scale. Introns are also not drawn to scale. The approximate positions of identiﬁed mutations
are given, with identical mutations shown above each other. Green triangle p mutation resulting in premature truncation due to either small
insertion/deletion/nonsense or splice-site alterations; red triangle p in-frame alterations due to either missense base substitutions or in-frame
insertion/deletion; yellow triangle p splice-site mutations in which the precise pathogenic effect has not been identiﬁed. b, Pedigree structure
and mutations in selected families with JHF and ISH, showing wild-type and mutant CMG2 sequence. The splice-site mutation in family C
results in insertion of 4 bases and a frameshift.
data suggest that tissue-speciﬁc and/or domain-restricted
differences in CMG2 function may exist. However, there
is also evidence that mutation class and position are not
sufﬁcient to account for all clinical variability, since cases
in families C and F that are homozygous for the same
founder mutation (IVS131GrA) that results in a trans-
lational frameshift have somewhat different clinical phe-
notypes. Family C consists of two living affected individ-
uals who presented with gingival hypertrophy and der-
mal lesions in childhood but developed signiﬁcant loco-
motor problems only in adolescence (Keser et al. 1999).
Family F harbors the same mutation as does family C
and comprises a single case subject. This subject devel-
oped gingival hypertrophy and perianal papules at 6
mo with joint swelling and limitation developing at 9
mo; she was never able to walk but had no evidence of
systemic disease typical of ISH, such as recurrent infec-
tions or gastrointestinal symptoms (Mancini et al. 1999).
Clearly, detailed clinical histories from additional cases
with conﬁrmed mutations are required, to evaluate these
putative genotype-phenotype associations, before mean-
ingful conclusions can be drawn.
The only known human gene that shows strong
homology to CMG2 is TEM8. TEM8 was original-
Hanks et al.: CMG2 Mutations Cause JHF and ISH 799
Table 3
Polymorphisms in CMG2
Location
Nucleotide
Change
Protein
Change
Intron 2 IVS2-43TrA
Intron 2 IVS2-4GrA
Intron 4 IVS48ArC
Intron 6 IVS629ArC
Intron 7 IVS754TrA
Exon 13 1597CrG P357A
Intron 13 IVS13-15ArG
Exon 16 1923GrA R465R
3′ UTR 2023CrT
ly identiﬁed as a gene differentially expressed in tu-
mor, as compared with normal colonic vasculature,
and is thus of potential interest as a target for anti-
angiogenic therapies in cancer (St Croix et al. 2000).
It is currently unknown whether CMG2 is similarly
differentially expressed in tumor tissues. Intriguing-
ly, both TEM8 and CMG2 have been shown to func-
tion as anthrax toxin receptors (Bradley et al. 2001;
Scobie et al. 2003). Furthermore, in an in vitro sys-
tem, a soluble version of the CMG2 vWA domain
has been shown to act as a potent antitoxin, sug-
gesting that CMG2 may prove useful in the devel-
opment of anti-anthrax treatments (Scobie et al.
2003). Our data give the ﬁrst insights into the in
vivo role of CMG2 and may be of relevance in un-
derstanding the role of CMG2—and, possibly, the
role of TEM8—in basement-membrane matrix pro-
cessing, tumor angiogenesis, and anthrax toxicity,
which understanding may in turn facilitate the ther-
apeutic exploitation of these proteins. Moreover, we
have identiﬁed a novel cytoplasmic domain that is
the deﬁning sequence hallmark of this protein fam-
ily. The function of this domain is unknown, but the
demonstration that in-frame deletions and missense
mutations restricted to the domain are pathogenic
indicates an important role that merits further inves-
tigation.
In conclusion, we have demonstrated that deleteri-
ous mutations inCMG2 cause both JHF and ISH. These
data provide the basis for diagnostic testing and ge-
netic counselling for families and will lead to better
understanding of the disease pathogenesis, which may
in turn help reduce the high morbidity and mortality
associated with these hyaline-deposition disorders.
Acknowledgments
We thank all the members of the families, for their inval-
uable contribution to this research; N. Akarsu, T. Ball, C.
Black, P. Byers, T. Hamada, M. McAvoy, J. Power, J. Pren-
diville, and V. Wessagowit, for assistance in obtaining sam-
ples; and A. Bateman, at the Wellcome Trust Sanger Institute,
for initial Pfam analysis of CMG2. M.E.C. and F.M.P. are
supported by the Medical Research Council and the Ehlers-
Danlos Support Group. A.S.F. is supported by the Swiss Na-
tional Science Foundation (3100A0–100485). This work was
supported by Institute of Cancer Research (U.K.).
Electronic-Database Information
Accession numbers and URLs for the data presented herein
are as follows:
BLAST, http://www.ncbi.nlm.nih.gov/BLAST/ (for BLAST and
tblastn, used in identiﬁcation of CMG2 paralogs and or-
thologs)
Center for Medical Genetics, http://research.marshﬁeldclinic
.org/genetics/ (for identiﬁcation of microsatellite markers)
ClustalW, http://www.ebi.ac.uk/clustalw/ (for alignment of hu-
man and orthologous CMG2 and TEM8 proteins)
Conserved Domain Database, http://www.ncbi.nlm.nih.gov/
Structure/cdd/cdd.shtml (for analysis of cytoplasmic domain)
Ensembl, http://www.ensembl.org/ (for mouse cmg2 [Ensembl
mouse peptide ENSMUSP00000046348] and fugu tem8
[Ensembl gene SINFRUG00000151577])
Expressed Sequence Tags Database, http://www.ncbi.nlm.nih
.gov/dbEST/
GenBank, http://www.ncbi.nlm.nih.gov/Genbank/ (for human
CMG2 cDNA [accession number AK091721] and protein
[accession number BAC03731], mouse cmg2 [accession num-
ber AAH03908], rat cmg2 [accession number XP_223745],
human TEM8 [accession number Q9H6X2], mouse tem8
[accession number XP_132709], rat tem8 [accession number
XP_232144], pig cytoplasmic domain [accession number
AW657469], cow cytoplasmic domain [accession number
AV599556], chicken cytoplasmic domain [accession num-
ber BI393979, and zebraﬁsh cytoplasmic domain [acces-
sion number BI867612])
Human BLAT Search, http://genome.ucsc.edu/cgi-bin/hgBlat
(for search engine used in alignment of CMG2 cDNAs with
genomic sequence)
MultAlin, http://prodes.toulouse.inra.fr/multalin/ (for align-
ment of cytoplasmic domains)
Online Mendelian Inheritance in Man (OMIM), http://www
.ncbi.nlm.nih.gov/Omim/ (for JHF and ISH)
Pfam, http://www.sanger.ac.uk/Software/Pfam/ (for analysis of
cytoplasmic domain)
Primer3, http://www-genome.wi.mit.edu/cgi-bin/primer/
primer3_www.cgi (for design of chromosome 4q21
microsatellite markers and CMG2 primers)
Prosite, http://us.expasy.org/prosite/ (for analysis of cyto-
plasmic domain)
UCSC Genome Bioinformatics, http://genome.ucsc.edu/ (for
Human Genome Project Working Draft sequence and iden-
tiﬁcation and position of microsatellite markers)
References
Allen PW (2001) Selected cases from the Arkadi M. Rywlin
International Slide Seminar: hyaline ﬁbromatosis. Adv Anat
Pathol 8:173–178
Balci S, Kulacoglu S, Senoz O, Vargel I, Erk Y, Onder S, Gokoz
A, Akarsu AN (2002) Juvenile hyaline ﬁbromatosis in three
800 Am. J. Hum. Genet. 73:791–800, 2003
sibs from a consanguineous family: clinical, histopatholog-
ical and immunohistochemical ﬁndings. Eur J Hum Genet
10:121
Bell SE, Mavilla A, Salazar R, Bayless KJ, Kanagala S, Max-
well SA, Davis GE (2001) Differential gene expression dur-
ing capillary morphogenesis in 3D collagen matrices: regu-
lated expression of genes involved in basement membrane
matrix assembly, cell cycle progression, cellular differenti-
ation and G-protein signalling. J Cell Sci 114:2755–2773
Bradley KA, Mogridge J, Mourez M, Collier RJ, Young JAT
(2001) Identiﬁcation of the cellular receptor for anthrax toxin.
Nature 414:225–229
Breier F, Fang-Kircher S, Wolff K, Jurecka W (1997) Juvenile
hyaline ﬁbromatosis: impaired collagen metabolism in hu-
man skin ﬁbroblasts. Arch Dis Child 77:436–440
Ganguly A, Rock MJ, Prockop DJ (1993) Conformation-sen-
sitive gel electrophoresis for rapid detection of single-base
differences in double-stranded PCR products and DNA frag-
ments: evidence for solvent-induced bends in DNA hetero-
duplexes. Proc Natl Acad Sci USA 90:10325–10329
Glover MT, Lake BD, Atherton DJ (1991) Infantile systemic
hyalinosis: newly recognised disorder of collagen? Pediatrics
87:228–234
——— (1992) Clinical, histologic and ultrastructural ﬁndings
in two cases of infantile systemic hyalinosis. Pediatr Derma-
tol 9:255–258
Ishikawa H, Maeda H, Takamatsu H, Saito Y (1979) Systemic
hyalinosis (juvenile hyaline ﬁbromatosis): ultrastructure of the
hyaline with particular reference to the cross-banded struc-
ture. Arch Dermatol Res 265:195–206
Iwata S, Horiuchi R, Maeda H, Ishikawa H (1980) Systemic
hyalinosis or juvenile ﬁbromatosis: ultrastructural and bio-
chemical study of skin ﬁbroblasts. Arch Dermatol Res 267:
115–121
Kayashima KI, Katagiri K, Shinkai H, Ono T (1994) Is juvenile
hyaline ﬁbromatosis a disease of type VI collagenosis? In:
Ishibashi Y, Nakagawa H, Suzuki H (eds) Electron micros-
copy in dermatology—basic and clinical research. Elsevier
Science, Amsterdam, pp 329–334
Keser G, Karabulut B, Oksel F, Calli C, Ustun E, Akalin T,
Kocanaogullari H, Gumusdis G, Doganavsargil E (1999)
Two siblings with juvenile hyaline ﬁbromatosis: case re-
ports and review of the literature. Clin Rheumatol 18:
248–252
Kitano Y, Horiki M, Aoki T, Sagami S (1972) Two cases
of juvenile hyaline ﬁbromatosis: some histological, elec-
tron microscopic, and tissue culture observations. Arch
Dermatol 106:877–883
Landing BH, Nadorra R (1986) Infantile systemic hyalinosis:
report of four cases of a disease fatal in infancy, apparently
different from juvenile systemic hyalinosis. Pediatr Pathol 6:
55–79
Lubec B, Steinbert I, Breier F, Jurecka W, Pillwein K, Fang-
Kircher S (1995) Skin collagen defects in a patient with ju-
venile hyaline ﬁbromatosis. Arch Dis Child 73:246–248
Mancini GMS, Stojanov L,Willemsen R, KleijerWJ, Huijmans
JGM, van Diggelen OP, de Klerk JBC, Vuzevski VD, Oranje
AP (1999) Juvenile hyaline ﬁbromatosis clinical heteroge-
neity in three patients. Dermatology 198:18–25
Mayer-da-Silva A, Poiares-Baptista A, Guerra Rodrigo F, Teresa-
Lopez M (1988) Juvenile hyaline ﬁbromatosis: a histologic
and histochemical study. Arch Pathol Lab Med 112:928–931
Nezelof C, Letourneux-Toromanoff B, Griscelli C, Girot R,
Saudubray JM, Mozziconacci P (1978) La ﬁbromatose
disseminee douloureuse (hyalinose systemique). Arch Fr
Pediatr 35:1063–1074
RahmanN, DunstanM, TeareMD,Hanks S, Edkins SJ, Hughes
J, Bignell GR, Mancini G, Kleijer W, Campbell M, Keser G,
Black C, Williams N, Arbour L, Warman M, Superti-Furga
A, Futreal PA, Pope FM (2002) The gene for juvenile hyaline
ﬁbromatosis maps to chromosome 4q21. Am J Hum Genet
71:975–980
Remberger K, Krieg T, Kunze D, Weinmann HM, Hubner G
(1985) Fibromatosis hyalinica multiplex (juvenile hyaline
ﬁbromatosis), light microscopic, electron microscopic, im-
munohistochemical and biochemical ﬁndings. Cancer 56:
614–624
Richter D, Bode H, Debatin KM, Mohr W (1999) Juvenile hya-
line ﬁbromatosis. Monatsschr Kinderheilkd 147:473–476
Sahn EE, Salinas CF, Sens MA, Key J, Swiger FK, Holbrook
KA (1994) Infantile systemic hyalinosis in a black infant.
Pediatr Dermatol 11:52–60
Scobie HM, Rainey GJ, Bradley KA, Young JA (2003) Human
capillary morphogenesis protein 2 functions as an anthrax
toxin receptor. Proc Natl Acad Sci USA 100:5170–5174
St Croix B, Rago C, Velculescu V, Traverso G, Romans KE,
Montgomery E, Lal A, Riggins GJ, Lengauer C, Vogelstein
B, Kinzler KW (2000) Genes expressed in human tumor
endothelium. Science 289:1197–1202
Stucki U, Spycher MA, Eich G, Rossi A, Sacher P, Steinmann,
Superti-Furga A (2001) Infantile systemic hyalinosis in sib-
lings: clinical report, biochemical and ultrastructural ﬁndings
and review of the literature. Am J Med Genet 100:122–129
